Dr Harry Destecroix, 31, co-founded Ziylo while studying for his PhD at the University of Bristol four years ago. It created a new technology that can be developed to treat diabetes more effectively. Pharmaceutical giant Novo Nordisk’s purchase means it now has full rights to develop glucose responsive insulins, as reported by the BBC. Destecroix said he hoped the sale will offer ground-breaking treatment for diabetics. Ziylo, a university spin-out company, developed a synthetic molecule which works by binding glucose in the bloodstream more effectively. Danish firm Novo Nordisk, one of the biggest manufacturers of diabetes medicines, will now aim to use this molecule to develop a new type of insulin which aims to help diabetics manage their condition more safely. www.bbc.co.uk/Ziylo
News items and features like this appear in the Desang Diabetes Magazine, our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. We just need your email address to subscribe you (it’s free, and you can easily unsubscribe should you wish to).